HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target

Benzinga · 12/30/2025 13:33
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.